Fertility

Why a Karyotype Gets Ordered After Repeated Loss

Save

Most recurrent pregnancy loss traces back to a chromosome error in the embryo itself, not in either parent — but a minority of cases involve a rearrangement carried, harmlessly, by one partner. A karyotype test is how that minority gets identified, separating a treatable structural cause from the more common, less predictable kind of loss.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why a Karyotype Gets Ordered After Repeated Loss

A karyotype test looks at the number and structure of both partners' chromosomes, and it's typically ordered after repeated pregnancy loss rather than after a single miscarriage, since a parental chromosome rearrangement is uncommon but disproportionately likely to explain a pattern of repeated losses rather than one isolated event.

How many losses prompts testing varies by clinic and by other factors, like age and whether a prior loss was tested and found chromosomally normal. Some clinics begin a recurrent miscarriage workup after two miscarriages in a row, particularly for an older patient, while others wait for three; there's no single number that applies to every situation the same way.

What the Test Actually Looks At

The test itself is a simple blood draw from each partner, sent to a lab where the chromosomes are grown, stained, and examined under a microscope for their number and structure. It's looking specifically for a balanced rearrangement — most often a balanced translocation, where two chromosomes have swapped pieces without losing or gaining genetic material overall.

A balanced translocation doesn't show up as a health problem for the person carrying it, since all the genetic material is still present, just rearranged differently. The risk shows up one generation down: when that person's chromosomes divide to form eggs or sperm, the rearranged pieces can be distributed unevenly, producing an embryo with too much or too little genetic material — a recognized cause of early pregnancy loss.

Most Recurrent Loss Isn't From a Parental Chromosome Problem

A parental chromosome rearrangement is found in only a minority of couples tested after recurrent loss. Most recurrent pregnancy loss instead traces back to a chromosome error that occurred in the embryo itself during early cell division, unrelated to either parent's own chromosome structure, and that kind of error becomes more common as maternal age increases.

That distinction matters for what a normal karyotype result actually means: it rules out a parental structural cause, but it doesn't mean a future pregnancy is free of chromosomal risk, since embryo-level errors can still occur independent of anything detectable in either partner's own chromosomes. A normal result is genuinely useful information — it just answers a narrower question than it might seem to at first.

What a Balanced Translocation Result Means Going Forward

Finding a balanced translocation in one partner doesn't mean pregnancy isn't possible — many carriers go on to have healthy pregnancies, sometimes without any additional intervention beyond knowing what to watch for and discussing the specific rearrangement with a genetics specialist early rather than after another loss.

What it does change is the conversation: genetic counseling becomes part of the plan, and options range from continuing to try naturally, knowing the miscarriage risk is elevated for that couple, to using IVF with genetic testing of embryos to identify which ones carry a balanced or normal chromosome set before transfer. Which path makes sense depends on the specific rearrangement found, since not all translocations carry the same risk profile.

Karyotype Testing vs. PGT-A: Two Different Tests, Often Confused

A parental karyotype test and PGT-A — preimplantation genetic testing for aneuploidy, done on embryos during IVF — are frequently confused with each other, but they answer different questions, for different people, at different points in the process, and mixing them up can lead to the wrong test being requested.

Karyotype testing looks at the parents, once, to check for a structural rearrangement that could explain a pattern of loss. PGT-A looks at embryos created during a later IVF cycle, screening each one for the right chromosome count before transfer. Current guidance is cautious about PGT-A's routine value: recent large trials found similar overall pregnancy outcomes with or without it in good-prognosis patients, so it isn't automatically the right add-on for everyone, even for a couple who has already found a parental translocation 12.

If IVF With Genetic Testing Is the Next Step

For a couple with a known parental translocation who chooses IVF with embryo genetic testing, the goal is identifying embryos with a balanced or fully normal chromosome set before transfer, which lowers the chance of another chromosome-related loss from that specific rearrangement.

Standard practice in this situation, as in IVF generally, favors transferring a single embryo rather than multiple ones, since multiple gestation carries meaningfully higher risk to both the pregnancy and the parent carrying it, without meaningfully improving the odds when a genetically screened embryo is available 3. That guidance applies regardless of how the embryo was selected — the reasoning is about the pregnancy, not the testing method that got there.

Where This Fits in a Broader Recurrent-Loss Workup

Karyotype testing is one piece of a recurrent loss workup, not the whole of it. Testing for a blood clotting disorder — APS and miscarriage are linked closely enough that antiphospholipid syndrome testing is usually included — plus uterine cavity evaluation and thyroid and hormone testing, typically happens alongside karyotype testing rather than one test at a time.

The same general timeline that applies to any fertility evaluation applies here too: earlier evaluation is generally recommended for women 35 and older, since age affects both the workup's urgency and its interpretation 4. Restarting folic acid ahead of trying again is also part of standard preconception care regardless of what the karyotype and the rest of the workup ultimately show 5. Questions about conceiving after loss — how soon is reasonable to try again — are worth separating from the genetic workup itself, since physical readiness and the testing timeline don't have to move together. For anyone choosing where to have this evaluation done, ASRM patient consultation guidance is a reasonable starting point for what a thorough recurrent-loss clinic visit should actually cover.

Common questions

It varies by clinic and by individual factors like age. Some clinics begin testing after two losses in a row, particularly for an older patient or when a prior loss was confirmed chromosomally normal, while others wait for three. There's no single number that applies the same way to everyone.

It means one partner carries a rearrangement of genetic material that doesn't affect their own health, but can be distributed unevenly when forming eggs or sperm, which is a recognized cause of early pregnancy loss. Many carriers still go on to have healthy pregnancies, sometimes without additional intervention.

No. Karyotype testing looks at the parents' own chromosomes, once, to check for a structural rearrangement. PGT-A looks at embryos created during a later IVF cycle. They answer different questions, and current guidance is cautious about PGT-A's value as a routine add-on even when a parental translocation has already been found.

A normal karyotype rules out a parental chromosome rearrangement as the cause, but it doesn't rule out a chromosome error occurring in the embryo itself, which is actually the more common cause of pregnancy loss overall and becomes more likely with age. A normal result is useful, just narrower than it might seem.

A recurrent loss workup typically also includes testing for a blood clotting disorder like antiphospholipid syndrome, uterine cavity evaluation, and thyroid and hormone testing, done alongside the karyotype rather than one at a time.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When to Move Beyond a Standard Recurrent-Loss Timeline

  • —heavy bleeding, fever, or severe pelvic pain during a pregnancy loss, which needs prompt medical evaluation regardless of where testing stands
  • —a third consecutive loss without any testing yet completed, which is a reason to ask directly about starting a recurrent-loss workup rather than waiting for it to be offered
  • —a falling or non-rising result on repeat beta hCG testing in a new pregnancy, which needs prompt evaluation rather than waiting for a scheduled ultrasound

Heavy bleeding, fever, or severe pelvic pain during a pregnancy loss warrants same-day care or an emergency room visit.

This article explains why and how karyotype testing is used after recurrent pregnancy loss and is not a diagnosis. Results should be interpreted by a clinician or genetic counselor familiar with the specific rearrangement found and the couple's full history.

References

  1. 1.Practice Committees of ASRM and SART (2024). The use of preimplantation genetic testing for aneuploidy: a committee opinion. American Society for Reproductive Medicine (Fertility and Sterility). PMID 38762806 ✓That the value of PGT-A as a routine screen for all IVF patients has not been demonstrated, since recent trials found similar pregnancy outcomes with and without it — supporting cautious, non-routine framing even for a couple who has already found a parental translocation.
  2. 2.Munné S, et al. (STAR Study Group) (2019). Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial. Fertility and Sterility. doi:10.1016/j.fertnstert.2019.07.1346That a multicenter RCT found PGT-A did not improve ongoing-pregnancy rates versus morphology-based embryo selection in good-prognosis patients, corroborating cautious framing of PGT-A's routine value.
  3. 3.Practice Committees of ASRM and SART (2021). Guidance on the limits to the number of embryos to transfer: a committee opinion. American Society for Reproductive Medicine (Fertility and Sterility). linkThat transferring a single embryo is standard guidance to reduce multiple-gestation risk while preserving cumulative live-birth rates, applying regardless of how the transferred embryo was selected.
  4. 4.Practice Committee of ASRM (2023). Definition of infertility: a committee opinion. American Society for Reproductive Medicine (Fertility and Sterility). linkThe recommended timing to begin a fertility evaluation — 12 months under age 35, 6 months at 35 or older — which shapes how promptly a recurrent-loss workup is pursued.
  5. 5.US Preventive Services Task Force (2023). Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication. US Preventive Services Task Force (JAMA). link ✓That folic acid supplementation is recommended for anyone planning or capable of pregnancy, starting at least a month before conception, as part of standard preconception care.

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library